U.S. markets open in 8 hours 17 minutes

Eucrates Biomedical Acquisition Corp. (EUCRU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.15+0.05 (+0.50%)
At close: 9:30AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.10
Open10.10
Bid0.00 x 2200
Ask0.00 x 2200
Day's Range10.15 - 10.15
52 Week Range9.91 - 10.15
Volume4
Avg. Volume86,540
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering
      PR Newswire

      Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

      Eucrates Biomedical Acquisition Corp. (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the closing of its initial public offering of 10,000,000 units at an initial public offering price of $10.00 per unit. The units are listed on The Nasdaq Capital Market ("Nasdaq") and commenced trading under the ticker symbol "EUCRU" beginning on October 23, 2020. Each unit consists of one ordinary share of the Company and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one ordinary share of the Company at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "EUCR" and "EUCRW," respectively.

    • Eucrates Biomedical Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
      PR Newswire

      Eucrates Biomedical Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering

      Eucrates Biomedical Acquisition Corp. (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 10,000,000 units at an initial public offering price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market ("Nasdaq") and trade under the ticker symbol "EUCRU" beginning on October 23, 2020. Each unit consists of one ordinary share of the Company and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one ordinary share of the Company at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "EUCR" and "EUCRW," respectively.